TY - JOUR
T1 - Effect of plant stanol tablets on low-density lipoprotein cholesterol lowering in patients on statin drugs
AU - Goldberg, Anne C.
AU - Ostlund, Richard E.
AU - Bateman, Joyce H.
AU - Schimmoeller, Linda
AU - McPherson, Timothy B.
AU - Spilburg, Curtis A.
N1 - Funding Information:
This study was supported by Lifeline Technologies, Chesterfield, Missouri, and a Small Business Innovation Research Grant R43 HL 62780 from the National Institutes of Health, Bethesda, Maryland. Preventive cardiology
PY - 2006/2/1
Y1 - 2006/2/1
N2 - The objective of this study was to show that plant sterols in tablet form provide additional low-density lipoprotein (LDL) cholesterol lowering for patients on statin therapy. Dispersible phytosterol tablets were tested in a double-blind, placebo-controlled, parallel clinical trial. Twenty-six patients who were following the American Heart Association Heart Healthy Diet and on long-term statin therapy were studied for 9 weeks. After 3 weeks of placebo treatment, the subjects were randomized to receive either 1.8 g of soy stanols or placebo for 6 weeks in addition to their usual statin regimen. Stanol tablets reduced LDL cholesterol 9.1% (p = 0.007) or 12.2 mg/dl. Total cholesterol was reduced by 12.9 mg/dl (p = 0.03). A strong inverse correlation (rs = -0.82, p = 0.0007) was found between the baseline LDL cholesterol and the percent change in LDL cholesterol observed after stanol treatment. The additional LDL cholesterol lowering with stanol/lecithin tablets provided a potential adjunctive therapy for patients who have not reached their target LDL cholesterol goal during statin therapy.
AB - The objective of this study was to show that plant sterols in tablet form provide additional low-density lipoprotein (LDL) cholesterol lowering for patients on statin therapy. Dispersible phytosterol tablets were tested in a double-blind, placebo-controlled, parallel clinical trial. Twenty-six patients who were following the American Heart Association Heart Healthy Diet and on long-term statin therapy were studied for 9 weeks. After 3 weeks of placebo treatment, the subjects were randomized to receive either 1.8 g of soy stanols or placebo for 6 weeks in addition to their usual statin regimen. Stanol tablets reduced LDL cholesterol 9.1% (p = 0.007) or 12.2 mg/dl. Total cholesterol was reduced by 12.9 mg/dl (p = 0.03). A strong inverse correlation (rs = -0.82, p = 0.0007) was found between the baseline LDL cholesterol and the percent change in LDL cholesterol observed after stanol treatment. The additional LDL cholesterol lowering with stanol/lecithin tablets provided a potential adjunctive therapy for patients who have not reached their target LDL cholesterol goal during statin therapy.
UR - http://www.scopus.com/inward/record.url?scp=31144479575&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2005.08.056
DO - 10.1016/j.amjcard.2005.08.056
M3 - Article
C2 - 16442399
AN - SCOPUS:31144479575
SN - 0002-9149
VL - 97
SP - 376
EP - 379
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 3
ER -